PUT - SPRINTER OPEN END - MODERNA | Market Closed - Borsa Italiana 04:04:59 2024-05-03 pm EDT | ||
| 9.21 EUR | 0.00% |
|
| Current month | -12.10% | ||
| 1 month | -17.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 9.37 | +1.74% | 84 |
| 24-05-02 | 9.21 | -13.60% | 130 |
| 24-04-30 | 10.66 | +1.62% | 111 |
| 24-04-29 | 10.49 | -3.23% | 95 |
| 24-04-26 | 10.84 | -1.28% | 96 |
Real-time Borsa Italiana
Last update May 03, 2024 at 04:04 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| F25163 | |
| ISIN | DE000VV2LSQ8 |
| Date issued | 2022-06-09 |
| Strike | 223.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 7.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.79 € |
|---|---|
| Lowest since issue | 0.456 € |
| Spread | 0.02 € |
| Spread % | 0.22% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
125
USD
Average target price
138.3
USD
Spread / Average Target
+10.65%
- Stock Market
- Certificates
- F25163 Certificat
